Related Experiment Video
Updated: Apr 15, 2026

An Ex vivo Assay to Study Candida albicans Hyphal Morphogenesis in the Gastrointestinal Tract
Published on: July 1, 2020
Fatal Breakthrough Mucormycosis in an Acute Myelogenous Leukemia Patient while on Posaconazole Prophylaxis
Seung Hun Kang1, Hyun Seon Kim1, Myoung Nam Bae1
1Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Abstract:
Posaconazole is a new oral triazole with broad-spectrum antifungal activity. Posaconazole has also shown a significant advantage of preventing invasive fungal infection compared to fluconazole or itraconazole in patients with prolonged neutropenia. Indeed, posaconazole has been commonly used for antifungal prophylaxis in patients undergoing remission induction chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome. We experienced a case of fatal mucormycosis despite posaconazole prophylaxis. To our knowledge, this is the first reported case of fatal breakthrough mucormycosis in a patient receiving posaconazole prophylaxis during remission induction chemotherapy in Korea. This case demonstrated that breakthrough fungal infection can occurs in patients receiving posaconazole prophylaxis because of its limited activity against some mucorales.
Insights
Posaconazole prophylaxis can fail, leading to fatal mucormycosis in leukemia patients. This case highlights posaconazole
Area of Science:
- Mycology
- Infectious Diseases
- Hematology
Background:
- Posaconazole is a broad-spectrum triazole antifungal.
- It is used for prophylaxis against invasive fungal infections in neutropenic patients, particularly those with acute myelogenous leukemia (AML) or myelodysplastic syndrome (MDS).
- Posaconazole has demonstrated superior efficacy over fluconazole and itraconazole in preventing fungal infections.
Purpose of the Study:
- To report the first case of fatal breakthrough mucormycosis in Korea.
- To highlight the limitations of posaconazole prophylaxis against certain fungi.
Main Methods:
- Case report of a patient undergoing remission induction chemotherapy for AML.
- The patient received posaconazole prophylaxis.
- The patient developed and succumbed to mucormycosis.
Main Results:
- A patient on posaconazole prophylaxis developed fatal mucormycosis.
- This represents a breakthrough fungal infection despite appropriate prophylaxis.
- The limited activity of posaconazole against Mucorales was implicated.
Conclusions:
- Posaconazole prophylaxis may not be fully effective against all invasive fungal infections.
- Breakthrough mucormycosis can occur even with posaconazole use.
- Physicians should be aware of posaconazole's limitations, especially against Mucorales in high-risk patients.
Related Concept Videos
Antifungal Agents
Fungal Group Zygomycota
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
